Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial

American Journal of Ophthalmology

Volumn 149, Issue 2, 2010, Pages

  Reibaldi, Michele ^a   Cardascia, Nicola ^b   Longo, Antonio ^a   Furino, Claudio ^b   Avitabile, Teresio ^a   Faro, Salvatore ^a   Sanfilippo, Marisa ^a   Russo, Andrea ^a   Uva, Maurizio Giacinto ^a   Munno, Ferdinando ^a   Cannemi, Vincenzo ^a   Zagari, Marco ^a   Boscia, Francesco ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CHOROID; CLINICAL TRIAL; FEMALE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERFUSION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 73549117001     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.08.026     Document Type: Article

References (35)

1. Wang M., Munch I.C., Hasler P.W., et al. Central serous chorioretinopathy. Acta Ophthalmol 86 (2008) 126-145
2. Ober M.D., Yannuzzi L.A., Do D.V., et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 112 (2005) 2088-2094
3. Jalkh A.E., Jabbour N., Avila M.P., et al. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 91 (1984) 1544-1548
4. Ie D., Yannuzzi L.A., Spaide R.F., et al. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol 77 (1993) 349-353
5. Yannuzzi L.A., Shakin J.L., Fisher Y.L., and Altomonte M.A. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91 (1984) 1554-1572
6. Iida T., Yannuzzi L.A., Spaide R.F., et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23 (2003) 1-7
7. Ficker L., Vafidis G., While A., and Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72 (1988) 829-834
8. Guyer D.R., Yannuzzi L.A., Slakter J.S., et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112 (1994) 1057-1062
9. Spaide R.F., Hall L., Haas A., et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16 (1996) 203-213
10. Pikkel J., Beiran I., Ophir A., and Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 109 (2002) 1723-1725
11. Fabianovà J., Porubskà M., and Cepilovà Z. Central serous chorioretinopathy-treatment with beta blockers [in Slovak]. Cesk Slov Oftalmol 54 (1998) 401-404
12. Burumcek E., Mudun A., Karacorlu S., and Arslan M.O. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 104 (1997) 616-622
13. Yannuzzi L.A., Slakter J.S., Kaufman S.R., and Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 2 (1992) 103-114
14. Chan W.M., Lam D.S., Lai T.Y., et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87 (2003) 1453-1458
15. Yannuzzi L.A., Slakter J.S., Gross N.E., et al. Indocyanine green angiographyguided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23 (2003) 288-298
16. Battaglia Parodi M., Da Pozzo S., and Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23 (2003) 235-237
17. Canakis C., Livir-Rallatos C., Panayiotis Z., et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 136 (2003) 750-752
18. Cardillo Piccolino F., Eandi C.M., Ventre L., et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23 (2003) 752-763
19. Taban M., Boyer D.S., Thomas E.L., and Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137 (2004) 1073-1080
20. Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240 (2002) 748-757
21. Schmidt-Erfurth U., Laqua H., Schlotzer-Schrehard U., et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120 (2002) 835-844
22. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 26 (2006) 239-242
23. Yaman A., Arikan G., Saatci A.O., and Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol 303 (2007) 69-73
24. Stewart J.M. Half dose verteporfin PDT for central serous chorioretinopathy. Br J Ophthalmol 90 (2006) 805-806
25. Reibaldi M., Boscia F., Avitabile T., et al. Low-fluence photodynamic therapy in long-standing chronic central serous chorioretinopathy with foveal and gravitational atrophy. Eur J Ophthalmol 19 (2009) 154-158
26. Michels S., Hansmann F., Geitzenauer W., and Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 47 (2006) 371-376
27. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials. TAP report. Arch Ophthalmol 117 (1999) 1329-1345
28. Miller J.W., Schmidt-Erfurth U., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117 (1999) 1161-1173
29. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration. 2-year results of a randomized clinical trial. Arch Ophthalmol 123 (2005) 448-457
30. Chan W.M., Lai T.Y., Lai R.Y., et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28 (2008) 85-93
31. Lai T.Y., Chan W.M., and Lam D.S. Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy. Am J Ophthalmol 137 (2004) 826-833
32. Loo R.H., Scott I.U., Flynn Jr., et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22 (2002) 19-24
33. Schmidt-Erfurth U., Schloetzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
34. Henderson B.W., Gollnick S.O., Snyder J.W., et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64 (2004) 2120-2126
35. Framme C., Flucke B., and Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol 244 (2006) 773-781